The APOL1 variants predominantly affect podocytes, key cells in the kidney glomerulus [25,26,27], leading to compromised glomerular filtration barrier integrity, proteinuria, and eventual end-stage renal disease (ESRD) [28,29]. This evidence concerns the gene APOL1 and chronic kidney disease.